title: Human papillomavirus in high-grade cervical lesions: Austrian data of a European multicentre study.
abstract: BACKGROUND
  The purpose is to present the Austrian data of an observational, cross-sectional, multicentre study conducted in 13 European countries. This study was undertaken to assess human papillomavirus (HPV) type distribution in high-grade cervical lesions.
  
  
  METHODS
  Two hundred and ninety cases of high-grade cervical intraepithelial neoplasia (CIN2, CIN3) or adenocarcinoma in situ of the cervix from 2004 to 2007 were analysed by histopathological review and polymerase chain reaction for HPV.
  
  
  RESULTS
  Two hundred and nine cases were "histologically eligible" and of those 206 were HPV+. Median age was 34 years (19-76 years). CIN3 was the most frequent diagnosis (64.6 %), followed by CIN2/3 (19.4 %) and CIN2 (13.6 %). Adenocarcinoma in situ was only detected together with a squamous lesion in 2.4 % cases. Majority of women (75.2 %) were infected with a single HPV type, 98.1 % of them with high-risk HPV types: HPV 16 (56.1 %), HPV 33 (12.3 %), HPV 31 (11.0 %), HPV 18 (3.9 %), HPV 35 (3.9 %), HPV 51 (3.2 %) and HPV 52 (2.6 %), HPV 58 (1.9 %) and HPV 45 (0.6 %). The low-risk HPV 6 was found in 1.3 % cases. Forty-six lesions (22.3 %) contained multiple infections, 71.1 % of those were HPV 16 or 18 and 91.1 % were HPV 16, 18, 31, 33 or 45 positive.
  
  
  CONCLUSIONS
  These Austrian data clearly demonstrate that HPV 16 is the predominant type in high-grade CIN, the immediate precursor lesions of cervical cancer. More than 60 % of the lesions were associated with HPV 16 and 18 and more than 85 % with HPV 16, 18, 31, 33 or 45. The prevalence of adenocarcinoma in situ is underestimated, since its detection is difficult with the current cytology screening.
authors.affiliation: Department of Gynaecology and Obstetrics, Comprehensive Cancer Center, Medical University of Vienna, Währingergürtel 18-20, 1090, Vienna, Austria, elmar.joura@meduniwien.ac.at.
authors.forename: Lucia
authors.initials: L
authors.lastname: Rössler
authors.forename: Olaf
authors.initials: O
authors.lastname: Reich
authors.forename: Reinhard
authors.initials: R
authors.lastname: Horvat
authors.forename: Sabrina Collas
authors.initials: SC
authors.lastname: de Souza
authors.forename: Katsyarina
authors.initials: K
authors.lastname: Holl
authors.forename: Elmar A
authors.initials: EA
authors.lastname: Joura
mesh_terms: D000230:Adenocarcinoma / Q000453:epidemiology / Q000473:pathology* / Q000821:virology*; D000328:Adult; D017677:Age Distribution; D000368:Aged; D052685:Alphapapillomavirus / Q000302:isolation & purification*; D015897:Comorbidity; D005060:Europe / Q000453:epidemiology; D005260:Female; D006801:Humans; D008875:Middle Aged; D060787:Neoplasm Grading; D015995:Prevalence; D012307:Risk Factors; D002583:Uterine Cervical Neoplasms / Q000453:epidemiology / Q000473:pathology* / Q000821:virology*; D002578:Uterine Cervical Dysplasia / Q000453:epidemiology / Q000473:pathology* / Q000821:virology*
references.citation: Lancet Oncol. 2008 May;9(5):425-34
references.pmid: 18407790
references.citation: Lancet Oncol. 2012 Jan;13(1):89-99
references.pmid: 22075171
references.citation: BMJ. 2012 Mar 27;344:e1401
references.pmid: 22454089
references.citation: Histopathology. 2007 Apr;50(5):629-35
references.pmid: 17394499
references.citation: Lancet Infect Dis. 2012 Oct;12(10):781-9
references.pmid: 22920953
references.citation: Cancer Epidemiol Biomarkers Prev. 2005 Sep;14(9):2191-9
references.pmid: 16172231
references.citation: BJOG. 2010 Feb;117(3):258-67
references.pmid: 19943823
references.citation: Lancet. 2007 May 19;369(9574):1693-702
references.pmid: 17512854
references.citation: Obstet Gynecol. 2001 Jun;97(6):890-2
references.pmid: 11384691
references.citation: CA Cancer J Clin. 2005 Mar-Apr;55(2):74-108
references.pmid: 15761078
references.citation: J Low Genit Tract Dis. 2008 Jan;12(1):8-10
references.pmid: 18162805
references.citation: Lancet. 2006 Feb 11;367(9509):489-98
references.pmid: 16473126
references.citation: J Clin Virol. 2005 Mar;32 Suppl 1:S16-24
references.pmid: 15753008
references.citation: Eur J Obstet Gynecol Reprod Biol. 2012 May;162(1):16-20
references.pmid: 22377225
references.citation: N Engl J Med. 2007 May 10;356(19):1915-27
references.pmid: 17494925
references.citation: J Clin Microbiol. 2002 Mar;40(3):979-83
references.pmid: 11880426
references.citation: Lancet. 2009 Jul 25;374(9686):301-14
references.pmid: 19586656
references.citation: Am J Obstet Gynecol. 2007 Dec;197(6):566-71
references.pmid: 18060938
references.citation: J Clin Microbiol. 2006 Sep;44(9):3292-8
references.pmid: 16954263
references.citation: Vaccine. 2012 Nov 20;30 Suppl 5:F157-67
references.pmid: 23199959
references.citation: BMJ. 2008 Sep 18;337:a1284
references.pmid: 18801868
references.citation: Lancet. 2007 Sep 8;370(9590):890-907
references.pmid: 17826171
references.citation: Int J Gynecol Pathol. 2002 Oct;21(4):416-7
references.pmid: 12352192
references.citation: Stat Med. 1998 Apr 30;17(8):857-72
references.pmid: 9595616
references.citation: Lancet Oncol. 2012 Jan;13(1):100-10
references.pmid: 22075170
references.citation: Int J Cancer. 2007 Aug 1;121(3):621-32
references.pmid: 17405118
references.citation: J Infect Dis. 2009 Apr 1;199(7):926-35
references.pmid: 19236279
references.citation: Int J Cancer. 2011 Mar 15;128(6):1344-53
references.pmid: 20949623
references.citation: Int J Cancer. 2011 Mar 15;128(6):1354-62
references.pmid: 20506504
references.citation: Int J Cancer. 2013 Feb 15;132(4):854-67
references.pmid: 22752992
references.citation: Wien Klin Wochenschr. 2008;120(21-22):666-71
references.pmid: 19116707